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Abstract  
Study Objective 
Comparison and study of post cesarean analgesia and side effect profile of epidural 0.125% 
bupivacaine-fentanyl v/s 0.125% bupivacaine-nalbuphine v/s 0.125% bupivacaine – butorphanol.  
Design 
Randomized, double-blinded study. 
80 ASA physical status I and II women, aged 20-30 years, undergoing Elective Cesarean Section 
Interventions  
 Patients were randomly allocated to four groups during the postoperative period to receive one 
of four epidural regimens: Group 1(NS): 10ml of 0.125% Bupivacaine + 1ml of Normal Saline; 
Group 2(FENT) 10ml of 0.125% Bupivacaine +  50ug of Fentanyl (1ml); Group 3(NALB) 10ml 
of 0.125% Bupivacaine + 5mg of Nalbuphine(0.5ml) +0.5ml of Normal saline to make it into 
1ml; Group 4 (BUTOR): 10ml of 0.125% Bupivacaine + 1mg of Butorphanol (1ml) 
Measurements 
Onset and duration of analgesia were recorded. Hemodynamic variables, pain scores, sedation 
scores, and respiratory rate were monitored for 24 hours. Frequency and severity of respiratory 
depression, sedation, pruritus, nausea, and vomiting were recorded. 
Main Results 
The data of only 77 patients were included for calculation because 3 patients were dropped from 
the study as they had patchy sensory blockade to an extent of converting to GA. There was no 
statistically significant difference in demographic parameters.  
The mean onset of analgesia and times to reach peak analgesia were significantly shorter 
while the mean durations of analgesia were significantly longer in the groups receiving fentanyl, 
nalbuphine & butorphanol than in the group receiving bupivacaine alone.  
The onset of analgesia was earliest with Butorphanol group( 3.42min )  followed by 
fentanyl group(4.20min  ),  Nalbuphine group(5.42min  )  & finally by control group(8.22min). 
The  duration of analgesia was maximum with Butorphanol group (mean of 360min), followed 
by Fentanyl group (mean of 280min), Nalbuphine group (mean of 245) & control group (mean of 
211min).  
Satisfaction with the pain relief given was assessed by 1. Ability for independent side to 
side movement  2. VAS for satisfaction. It was observed that satisfaction was more with 
Butorphanol group followed by Nalbuphine group, Fentanyl group & by control group in the 
descending order. 
Sedation was observed in all the groups (Control – 17%, Fentanyl – 25%, Nalbuphine – 
58%, Butorphanol – 63%. Butorphanol & Nalbuphine groups had more incidence of sedation & 
higher grades of sedation (Grade 4) 
Nausea & Vomiting was observed in both control group (incidence of 6% ) & fentanyl 
group (incidence of 20%) 
Pruritus was observed only in the fentanyl group with a incidence of 15%.  
None of the patients developed hypotension, Bradycardia, respiratory depression. 
 
Conclusions 
Epidural 0.125% Bupivacaine combined with Butorphanol  produces significantly earlier onset, 
longer duration and better quality of analgesia than 0.125% Bupivacaine - Nalbuphine  
combination /  0.125% Bupivacaine -Fentanyl combination / 0.125% Bupivacaine alone and is 
safe in parturients. 
 
 
 
INTRODUCTION 
The perioperative period is associated with a variety of 
pathophysiologic responses that may be initiated or maintained by 
nociceptive input. Although these responses may have had a beneficial 
teleologic purpose, the same response to the iatrogenic nature of modern-
day surgery may be harmful. Uncontrolled perioperative pain may 
potentiate some of these perioperative pathophysiologies and increase 
patient morbidity and mortality. Hence  Postoperative pain relief  is very 
essential in improving perioperative care & hence quality of health care 
given to the patient. 
The concept of opiate receptor subtypes (mu1 & mu2, kappa and 
sigma) and the advent of drugs with receptor-specific agonist and 
antagonist properties have further expanded the role of epidural opioids 
for intraoperative, postoperative, and obstetrical uses.  Such opioids in 
combination with Local Anaesthetics are not only valuable in providing 
good analgesia, but also prolongs the duration of analgesia. Fentanyl, a 
synthetic opioid is a pure mu receptor agonist, and is highly lipid soluble. 
The mu receptor agonism leads to various side effects such as respiratory 
depression, nausea, vomiting, reduced GI motility, sedation & physical 
dependence. Hence the need of opioids with lesser side effects, but with 
good analgesic properties, led us to consider opioids agonist-antagonist – 
Butorphanol & Nalbuphine as additives to local anaesthetic (via epidural 
route) for postcesarean analgesia. 
Butorphanol, a synthetic opioid, is a strong  kappa receptor agonist, 
a weak mu - receptor agonist/antagonist, and is relatively lipid soluble.  
Nalbuphine, a synthetic mu-receptor antagonist, kappa-receptor agonist 
opioid, is structurally related to the pure opioid agonist oxymorphone and 
the pure opioid antagonist naloxone. The antagonism at mu receptor  (in 
case of Butorphanol & Nalbuphine) causes reduction in side effects such 
as nausea/vomiting, respiratory depression & pruritus. For these reasons, 
the use of epidural  butorphanol / Nalbuphine in combination with 
0.125% Bupivacaine for post-Caesarean section analgesia should produce 
less respiratory depression and a reduced incidence of these side effects 
compared with other opioid-Local Anaesthetic combination. The purpose 
of this study was to evaluate and compare the duration of analgesia and 
the side effect profiles of equipotent doses of fentanyl (pure agonist)/ 
Nalbuphine (agonist-antagonist)/ and Butorphanol (agonist-antagonist)  
given epidurally along with Local Anaesthetic mixture (0.125% 
bupivacaine), in the postoperative period for elective cesarean section. 
REVIEW OF LITERATURE 
1. EPIDURAL ANATOMY & PHYSIOLOGY 
2. EPIDURAL ANAESTHESIA & ANALGESIA 
3. OPIOID PHARMACOLOGY 
4. EPIDURAL OPIOIDS 
5. POST CESAREAN ANALGESIA 
6. EFFECTS OF EPIDURAL ANAESTHESIA & OPIOIDS ON 
BREAST FEEDING 
7. VISUAL ANALOGUE SCALE (VAS) 
8. STUDY REVIEWS 
 
1. EPIDURAL ANATOMY AND PHYSIOLOGY                                             
Anatomy of the Epidural space: 
The epidural space surrounds the dural sac and is bounded by the 
posterior longitudinal ligament anteriorly, the ligamenta flava and the 
periosteum of the laminae posteriorly, and the pedicles of the spinal 
column and the intervertebral foramina containing their neural elements 
laterally. The space communicates freely with the paravertebral space 
through the intervertebral foramina. Superiorly, the space is anatomically 
closed at the foramen magnum where the spinal dura attaches with the 
endosteal dura of the cranium. Caudally, the epidural space ends at the 
sacral hiatus which is closed by the sacrococcygeal ligament. The 
epidural space contains loose areolar connective tissue, semiliquid fat, 
lymphatics, arteries, an extensive plexus of veins, and the spinal nerve 
roots as they exit the dural sac and pass through the intervertebral 
foramina.  
 
 
 
  
 
 
 
The lumbar epidural space in adults is segmented and 
discontinuous. 
Areas of epidural fat under the ligamentum flavum extend under 
the laminae but are separated by areas where the posterior dura contacts, 
but does not adhere to, the periosteum of the lamina. This segmentation 
may impede the passage of an epidural catheter and promote coiling and 
misplacement. The anteroposterior dimension of the posterior space is 
greatest in the lumbar region and averages 5.0 - 6.0 mm in adult males.  
 The posterior epidural space becomes more continuous in the 
thoracic region. In the thoracic region the anteroposterior dimension of 
the posterior epidural space decreases but the space becomes more 
continuous. A thin layer of epidural fat extends between the lamina and 
the dura . Epidural catheters placed thoracically may pass easier because 
areas where the dura meets bone are fewer. 
In more cephalad cervicothoracic region, the epidural fat 
disappears and the dura directly contacts lamina. The shallow space 
provides little room for excessive needle advancement. A homogenous 
semifluid fat pad free of vessels or fibrous septation occupies the 
posterior epidural space. 
    
 
Presence of Dorsomedian ligamentous strands that extend from the 
ventral side of the vertebral arch and draw the dura posteriorly in a 
dorsomedian dural fold, the plica mediana dorasalis divides the posterior 
epidural space into lateral compartments and narrows the space in the 
midline. Investigators have proposed that this segmentation of the 
epidural space may occasionally impede epidural catheter placement, or 
cause maldistribution of local anesthetics and unilateral or patchy 
anesthesia. 
The open intervertebral foramina transmits intrabdominal pressure 
directly to the epidural space. Degenerative joint disease and aging can 
narrow the intervertebral foramina and prevent the spread of local 
anesthetic out of the foramina, resulting in greater longitudinal spread of 
local anesthetics in the epidural space. 
A rich venous plexus almost entirely fills the anterior epidural 
space. The anterior dura adheres tightly to the posterior longitudinal 
ligament, which stretches across the intervertebral discs to form the 
anterior epidural space between the posterior longitudinal ligament &  
periosteum of the vertebral body.  
As the size of the dural sac relative to the epidural space decreases 
at the L4-L5 level, the posterior longitudinal ligament falls away from the 
anterior dura, and fat fills the anterior epidural space. The increasing 
amounts of epidural fat anteriorly may contribute to the long latency of 
epidural anaesthesia typically observed in the L5 and S1 nerve roots. 
  
The epidural venous plexus is a valveless system that 
communicates with the basivertebral vein, the intracranial sigmoid, 
occipital, and basilar venous sinuses, and the azygous system. Drugs, air, 
or other material injected into the epidural space can potentially reach the 
heart or brain directly through this route. Abdominal and thoracic veins 
connect with the venous plexus through the intervertebral foramina, and 
transmit intraabdominal and intrathoracic pressure to the epidural space.  
Epidural space in pregnancy 
Chronically increased intraabdominal pressure or obstruction of the 
IVC can distend the epidural venous plexus, with important implications 
for epidural anesthesia. This increases the risk of intravascular 
cannulation with an epidural catheter. It also effectively decreases 
epidural space volume, allowing local anesthetics to distribute more 
widely with resulting greater degrees of block. Exposure to greater 
vascular surface area also potentially increases the risk for local 
anesthetic toxicity due to absorption from the epidural space. 
Physiological Effects of Epidural Blockade 
The segmental nerves in the thoracic and lumbar region contain 
somatic sensory, motor and autonomic (sympathetic) nerve fibres. 
Sensory and autonomic fibres have a smaller diameter and are more 
easily blocked than larger, more rapidly-conducting motor fibres.  
Effects on organ systems 
Cardiovascular system. Vasodilatation of resistance and 
capacitance vessels occurs, causing relative hypovolaemia and 
tachycardia, with a resultant drop in blood pressure. This is exacerbated 
by blockade of the sympathetic nerve supply to the adrenal glands, 
preventing the release of catecholamines. If blockade is as high as T2, 
cardioaccelarator fibres are blocked  and may lead to bradycardia. The 
overall result may be inadequate perfusion of vital organs and measures 
are required to restore the blood pressure and cardiac output, such as fluid 
administration and the use of vasoconstrictors.  
Respiratory system. Usually unaffected unless blockade is high 
enough to affect intercostal muscle nerve supply (thoracic nerve roots) 
leading to reliance on diaphragmatic breathing alone. This is likely to 
cause distress to the patient, as they may feel unable to breathe 
adequately. 
Gastrointestinal system. Blockade of sympathetic outflow (T5-
L1) to the GI tract leads to predominance of parasympathetic (vagus and 
sacral parasympathetic outflow), leading to active peristalsis and relaxed 
sphincters, and a small, contracted gut, which enhances surgical access.  
Endocrine system. Nerve supply to the adrenals is blocked leading 
to a reduction in the release of catecholamines. 
Genitourinary tract. Urinary retention is a common problem with 
epidural anaesthesia. A severe drop in blood pressure may affect 
glomerular filtration in the kidney if sympathetic blockade extends high 
enough to cause significant vasodilation. 
2. EPIDURAL ANAESTHESIA & ANALGESIA 
Epidural anaesthesia is a central neuraxial block technique which 
provides segmental blockade. The epidural space was first described by 
Corning in 1901, and Fidel Pages first used epidural anaesthesia in 
humans in 1921. In 1945 Tuohy introduced the needle which is still most 
commonly used for epidural anaesthesia. Improvements in equipment, 
drugs and technique have made it a popular and versatile anaesthetic 
technique, with applications in surgery, obstetrics and pain control. Its 
versatility means it can be used as an anaesthetic, as an analgesic 
adjuvant to general anaesthesia and for postoperative analgesia in 
procedures involving the lower limbs, perineum, pelvis, abdomen and 
thorax.  
Indications 
General 
Epidural anaesthesia can be used as sole anaesthetic for procedures 
involving the lower limbs, pelvis, perineum and lower abdomen. It is 
possible to perform upper abdominal and thoracic procedures under 
epidural anaesthesia alone, but the height of block required, with its 
attendant side effects, make it difficult to avoid significant patient 
discomfort and  risk. The advantage of epidural over spinal anaesthesia is 
the ability to maintain continuous anaesthesia after placement of an 
epidural catheter, thus making it suitable for procedures of long duration. 
This feature also enables the use of this technique into the postoperative 
period for analgesia, using lower concentrations of local anaesthetic drugs 
or in combination with different agents. 
Specific uses 
Hip and knee surgery. Internal fixation of a fractured hip is 
associated with less blood loss when central neuraxial block is used. The 
rate of deep venous thrombosis is reduced in patients undergoing total hip 
and knee replacement, when epidural anaesthesia is used. 
Vascular reconstruction of the lower limbs. Epidural anaesthesia 
improves distal blood flow in patients undergoing arterial reconstruction 
surgery. 
Amputation. Patients given epidural anaesthesia 48-72 hours prior 
to lower limb amputation may have a lower incidence of phantom limb 
pain following surgery 
Thoracic trauma with rib or sternum fractures. Adequate 
analgesia in patients with thoracic trauma improves respiratory function 
by allowing the patient to breathe adequately, cough and cooperate with 
chest physiotherapy.  
Obstetrics. Epidural analgesia is indicated in obstetric patients in 
difficult or high-risk labour, e.g. breech, twin pregnancy, pre-eclampsia 
and prolonged labour. Furthermore, Caesarean section performed under 
central neuraxial block is associated with a lower maternal mortality and 
better perioperative period 
Epidural anaesthesia for LSCS  
When flexibility is necessary, epidural catheter technique is often 
chosen. In addition, women with an indwelling epidural catheter for 
labour who require CS usually receive the local anaesthetics through that 
catheter. The ideal anaesthetics should provide rapid onset of sensory 
block with an appropriate duration of action. The most commonly used 
local anaesthetics in this setting are 2% lignocaine 10-20ml (with or 
without adrenaline 1:200 000) or 0.5% bupivacaine 10-20ml.  The latter 
has a longer duration of action, but a slower onset  compared with 
lignocaine. Local anaesthetic requirements are less in pregnant patients. 
Proposed mechanisms include hormone-related changes in the action of 
spinal cord neurotransmitters, potentiation of the analgesic effect of 
endogenous analgesic systems, increased permeability of the neural 
sheath or other pharmacokinetic ⁄ dynamic differences. Hence large 
volume of  local anaesthetic administered may be toxic & hence  to 
reduce the risk of toxicity the drug should be administered in fractionated 
doses. 
Factors Affecting Epidural Anaesthesia 
Site of injection After lumbar injection, analgesia spreads both 
caudally and, to a greater extent, cranially, with a delay at the L5 and S1 
segments, due to the large size of these nerve roots. After thoracic 
injection, analgesia spreads evenly from the site of injection. The upper 
thoracic and lower cervical roots are resistant to blockade due to their 
larger size. The epidural space in the thoracic region is usually smaller 
and a lower volume of local anaesthetic is needed. 
Dosage The dose required for analgesia or anaesthesia is 
determined by several factors but generally, 1-2ml of local anaesthetic is 
needed per segment to be blocked. The spread of local anaesthetic in the 
epidural space is unpredictable as the size of the epidural space is 
variable, as is the amount of local anaesthetic that leaks into the 
paravertebral space. 
The dose (in milligrams) is a function of the volume injected and 
the concentration of the solution. It is important to remember that 
sympathetic nerve fibres have the smallest diameter and are most easily 
blocked , even with low concentrations of local anaesthetic. With an 
epidural catheter,  incremental dosing is possible and this is important in 
preventing excessively high sympathetic block with hypotension. 
A useful concept is the "time to two-segment regression". This is 
the time from injection of the first dose of local anaesthetic to the point 
where maximum sensory level has receded by two segments. When two-
segment regression has occurred, approximately one half of the original 
dose should be injected to maintain the block. The time to two-segment 
regression for lignocaine is 90-150 minutes, and for bupivacaine it is 200-
260 minutes. 
Age, height & weight There is an age related decrease in the 
volume of local anaesthetic needed to achieve a given level of block, 
presumably due to a decrease in the size and compliance of the epidural 
space. The patient's height appears to correlate to some extent with the 
volume of local anaesthetic needed. The safest approach is to inject 
incremental doses and monitor the effect carefully. There is little 
correlation between the weight of a patient and the volume of local 
anaesthetic needed, although in morbidly obese patients the epidural 
space may be compressed due to the effect on intra-abdominal pressure, 
and a smaller volume of local anaesthetic is needed. Furthermore, venous 
engorgement of the epidural space due to compression of the azygos 
venous system may further reduce the volume of the epidural space &  
increase the risk of puncture of an epidural vein. 
Vasoconstrictor  With bupivacaine, the addition of adrenaline has 
not been shown to prolong anaesthesia, while with lignocaine; the 
addition of adrenaline (usually 1:200 000) does prolong the duration of 
action. However, vasoconstriction does reduce the amount of systemic 
absorption of local anaesthetic drugs, and reduces the risk of toxicity. 
Alkalinisation of local anaesthetics  Commercially available 
solutions of local anaesthetics have a pH between 3.5 and 5.5, for 
chemical stability and bacteriostasis. Most local anaesthetics are weak 
bases and exist in their ionised (hydrophilic) form at this pH. Since nerve 
blockade is dependent on penetration of the lipid nerve cell membranes, 
and the non-ionised (lipophilic) form crosses membranes more easily, it 
follows that raising the pH of the solution will increase the proportion of 
drug in the non-ionised form and thus enhance nerve membrane 
penetration and speed up the onset of blockade. The addition of 8.4% 
sodium bicarbonate (0.5ml per 10ml of local anaesthetic solution)  has 
become popular in achieving more rapid onset of blockade, for example, 
emergency Caesarean Section.  
Epidural Management and Choice of Drugs 
Once a catheter is placed, the filter and its connector are attached to 
the proximal end of the catheter. At this point, a test dose of local 
anaesthetic is injected to ensure that the catheter is not in the 
subarachnoid space. A small dose, e.g. 0.5% bupivacaine 3.5ml, bearing 
in mind the volume of the filter, which is about 1ml, is injected and the 
response noted over the next few minutes. This dose, if injected into the 
subarachnoid space, will cause complete surgical anaesthesia below the 
level of injection, and will be accompanied by the drop in blood pressure 
usually seen in spinal anaesthesia. It is unlikely to cause significant 
sensory block or hypotension if correctly injected into the epidural space. 
Following the test dose, the procedure for the administration of further 
local anaesthetic will depend on the purpose of the epidural. The 
important principle is that any bolus injection of local anaesthetic should 
be given incrementally, and the response carefully monitored, so that the 
practitioner can react promptly to any adverse reaction. Once a 
satisfactory block is established, whether for surgical anaesthesia, 
analgesia in labour or any other indication, the block can be maintained 
either by intermittent bolus  administration of local anaesthetic (with or 
without opioids) or as a continuous infusion, if the necessary equipment 
is available. 
Epidural analgesia: 
The use of epidural analgesia for pain relief was revolutionized by 
the use of epidural opioids after the discovery of opioid receptors in the 
dorsal horn of the spinal cord. Opioids have both presynaptic and 
postsynaptic effects in the dorsal horn and affect the modulation of 
nociceptive input but do not cause motor or sympathetic blockade. 
Analgesia occurs by way of a spinal mechanism (diffusion of drug into 
the spinal fluid) and through  supraspinal mechanism after systemic 
absorption.   
Low concentration local anaesthetics, opioids, or combinations of 
both are effective in the control of postoperative pain in patients 
undergoing abdominal and thoracic procedures. Epidural analgesia has 
been shown to minimize the effects of surgery on cardiopulmonary 
reserve, i.e. diaphragmatic splinting and the inability to cough adequately, 
in patients with compromised respiratory function, such as those with 
chronic obstructive airway disease, morbid obesity and in the elderly. 
Epidural analgesia allows earlier mobilization, reduces the risk of deep 
venous thrombosis, and allows better cooperation with chest 
physiotherapy, preventing chest infections.  
Advantages of Regional compared to GA for LSCS:  
Ability to extend height and duration of block, Low frequency and 
slower onset of  hypotension, Avoid tracheal intubation difficulty, 
Minimal risk of gastric aspiration, decreased blood loss, Avoidance of 
intentional dural puncture, Post-operative analgesia, positive breast 
feeding  influences, Minimal newborn depression, Avoid hangover 
effects of G.A, early bowel recovery after surgery & early ambulation. 
Disadvantages: 
Patchy anaesthesia, Slow onset, No intense block, Accidental dural 
puncture & PDPH, Accidental i.v. injection, epidural hematoma,  
 Catheter misplaced into the subarachnoid space - a total spinal 
(can occur), Neurological injury lasting less than 1 year (rare, about 1 in 
6,700), Epidural abscess formation (very rare, about 1 in 145,000).  
Neurological injury lasting longer than 1 year (extremely rare, about 1 in 
240,000)  
3. OPIOID PHARMACOLOGY: 
Opioid receptor types 
It is generally agreed that there are three major classes of receptors 
mediating opioid-induced analgesia. These are the mu-(1 & 2), kappa, 
and delta-opioid receptors . They are all blockable by naloxone an opioid 
receptor-specific competitive antagonist. There is also a receptor which 
binds opioids in a non-naloxone reversible fashion, referred to as the 
sigma opioid receptor, and it has no apparent role in mediating opioid-
induced analgesia. It may mediate the psychotomimetic effects of some 
opioids, apparently related to its ability to bind phencyclidine. 
 
CLASSIFICATION: 
Classification of Opioid Compounds 
 
Naturally Occurring  
    Morphine 
    Codeine 
    Papaverine 
    Thebaine 
Semisynthetic  
    Heroin 
    Dihydromorphone/morphinone 
    Thebaine derivatives (e.g., etorphine, buprenorphine) 
Synthetic  
    Morphinan series (e.g., levorphanol, butorphanol) 
    Diphenylpropylamine series (e.g., methadone) 
    Benzomorphan series (e.g., pentazocine) 
    Phenylpiperidine series (e.g., meperidine, fentanyl, sufentanil, alfentanil, remifentanil) 
 
 
Mechanism of Analgesia  
Pain control by opioids needs to be considered in the context of 
brain circuits modulating analgesia and the functions of the various types 
of receptors in these circuits. The analgesic effects of opioids arise from 
their ability to directly inhibit ascending transmission of nociceptive 
information from the spinal cord dorsal horn and to activate pain control 
circuits that descend from the midbrain, via the rostral ventromedial 
medulla (RVM), to the spinal cord dorsal horn. The µ-receptor produces 
analgesia within descending pain control circuits, at least in part by the 
removal of GABAergic (transmitting or secreting γ-aminobutyric acid) 
inhibition of RVM-projecting neurons in the PAG and spinally projecting 
neurons in the RVM. The actions of µ-receptor agonists are invariably 
analgesic, whereas those of κ-receptor agonists can be either analgesic or 
antianalgesic. The pain-modulating effects of κ-receptor agonists in the 
brainstem appear to oppose those of µ-receptor agonists. 
Local spinal mechanisms, in addition to descending inhibition, 
underlie the analgesic action of opioids. In the spinal cord, opioids act at 
synapses either presynaptically or postsynaptically. Opioid receptors are 
abundantly expressed in the substantia gelatinosa, where release of 
substance P from the primary sensory neuron is inhibited by opioids. 
The actions of opioids in the bulbospinal pathways are critical to 
their analgesic efficacy. Opioid actions in the forebrain clearly contribute 
to analgesia because decerebration prevents analgesia when rats are tested 
for pain sensitivity with the formalin test and microinjection of opioids 
into several forebrain regions is analgesic in this test. 
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Mood Alteration 
The mechanisms by which opioids produce euphoria, tranquility, 
and other alterations in mood (including rewarding properties) are not 
entirely clear. Behavioral and pharmacologic evidence points to the role 
of dopaminergic pathways, particularly those involving the nucleus 
accumbens. The locus ceruleus contains both noradrenergic neurons and 
high concentrations of opioid receptors and is postulated to play a critical 
role in feelings of alarm, panic, fear, and anxiety. Neural activity in the 
locus ceruleus is inhibited by both exogenous opioids and endogenous 
opioid peptides. 
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Major Receptor Types 
Μu κ δ* 
AGONIST    
Morphine (and codeine, oxycodone, 
meperidine, hydromorphone, ) 
Ag Ag  
 AGONISTS-ANTAGONISTS    
Buprenorphine  pAg Ant Ant 
Pentazocine  pAg Ag  
Nalbuphine  pAg Ag  
Butorphanol  pAg Ag  
ANTAGONISTS    
Naloxone  Ant Ant Ant 
Naltrexone  Ant Ant Ant 
Underlined item indicates  predominant receptor effects 
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 Equianalgesic Potent 
dose 
Duration of Analgesia 
(hr) 
Morphine 10mg 4-5 
Buprenorphine 0.3-0.4mg >6 
Butorphanol 2mg 3-4 
Nalbuphine 10mg 3-6 
Fentanyl 100ug 1 
 
                     
 
 
 
 
 
Fentanyl  
First synthesized in Belgium in late 1950 s. Introduced in medical 
practice in 1960 s as an intravenous anaesthetic agent. It is a 
phenylpiperidine derivative acts as a pure  agonist at mu opioid receptors. 
100 times more potent than morphine. Structurally related to meperidine. 
Pharmacokinetics  - Effect site equilibration time (b/w blood & 
brain) is  6 min. It is highly lipid soluble. Rapid redistribution 75% of 
initial dose undergoes first pass pulmonary uptake. N-Demethylation 
produces norfentanyl(main metabolite), which begins to appear in plasma 
as early as 1.5 minutes after injection & is excreted by kidneys.  Highly 
protein bound (79%-87%) and significant amounts (40%) are taken up by 
RBCs. 
The plasma concentration of fentanyl required for postoperative 
analgesia was approximately 1.5 ng/mL, but levels of at least 2 to 
3 ng/mL are usually required during surgery if the only inhaled agent is 
N2O. 
Preparations: Available as Intravenous injection, Transdermal 
patch(duragesic), Oral transmucosal fentanyl citrate(otfc), Push button 
fentanyl 
Uses  : Analgesia - Intravenous boluses of fentanyl (1 to 3 µg/kg), 
Infusion rates range from 0.01 to 0.05 µg/kg/min for fentanyl . In doses 
2-10microg/kg iv to blunt circulatory responses to laryngoscopy or 
surgical  stimulation. Large doses 25-50microg/kg  for opioid induction 
in cardiac surgeries. 
Side effects: Repeated doses or continuous infusions of fentanyl 
are most likely to result in significant depression of spontaneous 
ventilation, nausea & vomiting, pruritus, chest wall rigidity (which can be 
attenuated by co- administration of induction agents like Thiopentone & 
Muscle relaxants in case of General Anaesthesia) 
Nalbuphine 
Nalbuphine is an agonist-antagonist opioid that is structurally 
related to oxymorphone and naloxone and binds to µ-receptors, as well as 
to κ- and δ-receptors. Nalbuphine acts as an antagonist at the µ-receptor 
and as an agonist at the κ-receptor. Activation of supraspinal and spinal 
κ-receptors results in limited analgesia, respiratory depression, and 
sedation. Nalbuphine, like other agonist-antagonist compounds, interferes 
with the analgesia produced by pure µ-agonists.  
Mark W. Gunion et al - A key point in understanding the utility of 
nalbuphine is that while it binds readily to both the mu- and kappa-
receptors, its actions on these populations are divergent. When 
nalbuphine binds to mu-receptors it serves only to competitively displace 
other mu-agonists from the receptor, without itself displaying any agonist 
activity itself. At mu-receptors, then, nalbuphine has only antagonist 
effects, similar to those of naloxone. When nalbuphine binds to kappa-
receptors, however, it has an agonist activating effect. This pattern of 
binding and effects defines nalbuphine as a mixed agonist—antagonist. 
Pharmacokinetics: Equal in potency as an analgesic to morphine 
and ¼  as potent antagonist as  nalorphine. Nalbuphine is available only 
for parenteral use. The onset of effect is rapid (5 to 10 minutes), and its 
duration is long (3 to 6 hours) because of an extended plasma elimination 
half-life (5 hours). Metabolised in the liver and has an elimination half-
time of 3-6 hours. The pharmacokinetic profile of epidural nalbuphine 
was similar to that seen with iv injection. 
Nalbuphine (10 mg) caused no significant changes in systemic, 
pulmonary arterial, and pulmonary capillary wedge pressure in patients 
experiencing myocardial infarction. 
Uses : Nalbuphine has been administered as an analgesic 
supplement for conscious sedation or balanced anaesthesia and as an 
analgesic for postoperative and chronic pain problems. 10 mg  IM 
produces analgesia, 10-20 mg IV reverses postoperative depression of 
ventilation caused by fentanyl but maintains analgesia . Premedication 
with nalbuphine (0.1 mg/kg) in patients scheduled for cardiac surgery 
results in sedation, relief of anxiety, and respiratory depression similar to 
morphine (0.1 mg/kg), but it causes no significant hemodynamic changes. 
For postoperative patient-controlled epidural analgesia, the 
combination of hydromorphone, 0.075 mg/mL, and nalbuphine, 
0.04 mg/mL, resulted in a lower incidence of nausea and decreased need 
for bladder catheterization when compared with hydromorphone alone. 
 The problem is that nalbuphine, like other mixed  agonists—
antagonists, exhibits a ceiling effect. That is, increasing doses of drug 
produce increasing intensity of analgesia only up to a point; beyond that 
point, further increases in dose do not result in increased intensity of 
analgesia(1). 
Pugh GC  et al –  Br J Anaesth 1987;59:1356—63(2) 
The use of the opioid mixed agonist—antagonist nalbuphine as an 
analgesic agent provides a number of advantages. Used as the sole opioid 
analgesic, it can satisfactorily cover mild to moderate pain with a low 
incidence of side effects. The ceiling effect of nalbuphine, which prevents 
it from supplying sufficient analgesia to cover the most severe 
discomfort, also prevents increasing sedation and respiratory depression 
as the dose is increased, potentially providing an increased safety margin 
in comparison to mu-agonists. When nalbuphine is used concurrently 
with mu-agonists (e.g. morphine, hydromorphone, fentanyl), the benefits 
of both mu- and kappa-analgesia can be obtained, with simultaneously 
decreased incidence and severity of the common mu-agonist side effects 
(pruritis, nausea/emesis, constipation, urinary retention, respiratory 
depression and undesirable sedation).   
Side effects:  Sedation, Dysphoria , Withdrawal symptoms  
Butorphanol 
Synthetically derived opioid agonist - antagonist analgesic of the 
phenanthrene series. Dose as expressed as the tartrate salt.1mg of salt is 
equivalent to 0.68mg of free base. Butorphanol is an agonist at  
κ-receptors. Its activity at µ-receptors is either antagonistic or partially 
agonistic. 
Pharmacokinetics:  Binds with plasma protein to the extent of 
80%. Major metabolite is hydroxybutorphanol,while norbutorphanol is 
produced in small amount. It is available only in parenteral form. After 
intramuscular injection, the onset of effect is rapid, and peak analgesia 
occurs within 1 hour & the duration of action of butorphanol is similar to 
that of morphine, its plasma half-life is only 2 to 3 hours. 
In healthy volunteers, butorphanol (0.03 or 0.06 mg/kg IV) 
produces no or minimal cardiovascular changes. However, in patients 
with cardiac disease, butorphanol causes significant increases in cardiac 
index, left ventricular end-diastolic pressure, and pulmonary artery 
pressure. Butorphanol is subjected to less abuse and has less addictive 
potential than morphine or fentanyl does. Acute biliary spasm can occur 
after butorphanol, but increases in biliary pressure are less than after 
equipotent doses of fentanyl or morphine.  
Prepartation in Ampoules-  1mg /1 ml;  2mg /1 ml 
Uses: Moderate to severe postoperative pain-1mg iv single dose 
and repeated every 3-4hr. Effective dose range is  0.5-2mg i.v or 2mg i.m 
(1-4mg), Preoperative or preanesthetic medication- 2mg i.m 60 minutes 
before surgery. Supplement to balanced anesthesia-2 mg  i.v before 
induction or  0.5-1mg iv in increment doses, Relief of pre partum pain=1-
2mg iv/i.m. Transnasal butorphanol is effective in relieving migraine and 
postoperative pain. 
Side effects: Although butorphanol at dose of 10mg im causes as 
much respiratory depression as the same dose of morphine, higher doses 
reach a ceiling. Other side effects after butorphanol include drowsiness, 
sweating, nausea, and CNS stimulation. 
4. EPIDURAL OPIOIDS/ LOCAL ANAESTHETICS 
The addition of opioids to local anaesthetic solutions has gained 
popularity; as the opioids have a synergistic effect by acting directly on 
opioid receptors in the spinal cord. Various opioids, such as morphine (2-
5mg), fentanyl (50-100mcg) and diamorphine (2-4mg), have been used 
successfully both alone and in combination with local anaesthetic drugs, 
during labour, for intraoperative use and for postoperative analgesia. The 
combination of low-concentration local anaesthetic and low-
concentration mixtures of opioids, administered by slow infusion rather 
than as intermittent boluses has been shown to be very effective in the 
management of postoperative pain. 
Pethidine 25-75mg, in particular, has a structure similar to local 
anaesthetics and is effective in providing surgical anaesthesia and 
postoperative analgesia. 
Fentanyl is also used frequently in epidural 50-100ug along with 
Local Anaesthetics.  
All opioids given by this route have the potential to cause 
respiratory depression, and this should be borne in mind when the patient 
is discharged from the care of the anaesthetist. Patients should be 
managed postoperatively in an area with monitored care.  
Pharmacokinetics of epidural opioids 
Side effects of intrathecal and epidural opioids are caused by 
presence of the drug in either CSF or blood. Therefore, following 
administration of intrathecal and epidural opioids, side effects will be 
profoundly affected by their pharmacokinetic behaviour. Fentanyl and 
sufentanil are, respectively, approximately 800 and 1600 times as lipid-
soluble as morphine. When administered intrathecally or epidurally, 
therefore, morphine will exhibit slower onset and longer duration of 
antinociception and a higher incidence of  side effects. Fentanyl and 
sufentanil penetrate the spinal cord quickly, leaving little drug to ascend 
cephalad in cerebrospinal fluid. In contrast, morphine penetrates the 
spinal cord slowly, allowing considerable amounts of drug to ascend 
cephalad in cerebrospinal fluid.  
Following lumbar intrathecal morphine administration, appreciable 
cervical CSF concentrations occur one to five hours after injection, while 
cervical CSF concentrations of a highly lipophilic opioids, similarly 
administered, are minimal.  CSF ascends in a cephalad direction from the 
lumbar region, reaching the cisterna magna by one or two hours and the 
fourth and lateral ventricles by three to six hours. Highly lipophilic 
opioids are removed from CSF rapidly secondary to vascular reabsorption 
and spinal cord penetration. In contrast, morphine persists in 
cerebrospinal fluid for prolonged periods and may depend on 
reabsorption through arachnoid granulations for elimination. The terminal 
elimination half-life of morphine in CSF is similar to that in plasma, two 
to four hours.  
Following epidural administration, cerebrospinal fluid 
concentrations of fentanyl peak in 10 to 20 min  while sufentanil 
concentrations peak in about six minutes and that of morphine, peak in 
one to four hours. Furthermore, only about 3% of the dose of morphine 
administered epidurally crosses the dura to enter cerebrospinal fluid.(3) 
 The epidural space contains an extensive venous plexus. 
Therefore, vascular reabsorption following epidural administration of 
opioids is extensive. Epidural administration of morphine, fentanyl, or 
sufentanil produces opioid blood concentrations that are similar to an 
intramuscular injection of an equivalent dose. Following epidural 
administration, fentanyl blood concentrations peak at about five to ten 
minutes(4,5)  while sufentanll blood concentrations peak even faster(6).  In 
contrast, blood concentrations of morphine following epidural 
administration peak at about 10 to 15 min. 
Mark A. Chancy et al - Can J Anaesth 1995 / 42:I0 / (7) 
Advantages of Intrathecal and epidural opioids produce profound 
segmental antinociception in doses much smaller than would be required 
for comparable antinociception if administered systemically. 
Antinociception may be prolonged; when morphine is utilized, it may 
persist for days following a single injection.  Unlike the response to local 
anaesthetics, there is no motor, sensory, or autonomic blockade. Paralysis 
and hypotension, therefore, are absent. Another critical advantage over 
local anaesthetics is the availability of a specific opioid receptor 
antagonist, naloxone. 
Cohen et al - Reg Anesth 1991;16:141–9(8) 
Patients receiving IV patient-controlled analgesia and IM opioids 
report more severe pain after Cesarean section compared with those 
receiving intrathecal (IT) and epidural-administered opioids 
 
Neuraxial opioids; side effects 
Pruritus, Nausea and vomiting, Urinary retention, Respiratory 
depression 
Mental status changes, Central nervous system excitation, Herpes 
simplex labialis virus reactivation, Neonatal respiratory depression, 
Ocular dysfunction, Gastrointestinal dysfunction, Anaphylaxis 
Drug Correlation of Respiratory Depression with Dose 
Morphine Increases proportionally with dose 
Buprenorphine Ceiling effect at 0.15-1.2 mg in adults 
Butorphanol Ceiling effect at 30-60 µg/kg 
Nalbuphine Ceiling effect at 30 mg in adults 
Fentanyl Increases proportionally with dose 
 
A.D. Baxter et al:   Can J Anaesth 1991 / 38:2(9) 
Epidural opioids provide effective postoperative analgesia, but may 
have undesirable side-effects such as pruritus, urinary retention, nausea 
and vomiting, and most importantly respiratory depression(10). The 
incidence of severe respiratory depression is low, but mild carbon dioxide 
(CO2) retention and abnormal respiratory patterns are seen more 
frequently 
5. POST CESAREAN ANALGESIA 
Post-cesarean delivery pain relief is important. Good pain relief 
will improve mobility and can reduce the risk of thromboembolic disease, 
which is increased during pregnancy. Pain may also impair the mother’s 
ability to optimally care for her infant in the immediate postpartum period 
and may adversely affect early interactions between mother and infant. 
Pain and anxiety may also reduce the ability of a mother to breast-feed 
effectively. It is necessary that pain relief be safe and effective, that it not 
interfere with the mother’s ability to  move around and care for her infant, 
and that it result in no adverse neonatal effects in breast-feeding women. 
Systemic Administration: 
Intramuscular/Subcutaneous Injection: IM or subcutaneous 
administration of opioids is the most frequently used modality for post-
cesarean delivery pain relief. However, there are some limitations to their 
use. First, drug administration requires injection, often repeated, which 
may be uncomfortable for many women. Second, there is large inter-
individual variability in opioid pharmacokinetics and drug requirements, 
hence some have effective pain relief but have an increased incidence of 
unwanted effects, such as somnolence and sedation, whereas at smaller 
concentrations, pain relief may be inadequate. 
Patient-Controlled IV Analgesia: The device is programmable 
for the dose administered, a lockout interval, whether a basal infusion of 
drug is given, and as an added protection, maximum dosages within 
specified time periods. The advantage of IVPCA is that it reduces the 
peaks and valleys in blood drug concentrations and pain relief observed 
in post-cesarean delivery women. Pain relief with IVPCA has been 
shown to be superior to conventional IM opioids for pain relief in women 
having had a cesarean delivery. The most significant limitations to the use 
of IVPCA in postpartum women relate to the device itself and patient 
ability to use it correctly. 
Neuraxial Opioids:  
Spinal: Mechanism of Action - Opioids administered in the 
subarachnoid space appear to act principally on mu receptors in the 
substantia gelatinosa of the dorsal horn by suppressing excitatory 
neuropeptide release from C fibers. The degree of uptake from the 
cerebrospinal fluid by the dorsal horn is determined primarily by the 
physicochemical properties of the drug, and in particular, lipid solubility.  
 Uptake of opioids into the systemic circulation after intrathecal 
injection is usually not significant, as the doses typically used in the 
spinal space are small. This  is particularly important to breast-feeding 
women and is an advantage of neuraxial modes of post-cesarean delivery 
pain relief as compared with the larger doses of opioids required 
systemically. 
Epidural: Mechanicm of Action- a hydrophilic drug, such as 
morphine, is injected, it moves slowly across the arachnoid granulations 
there is a predominant spinal mechanism of analgesia after epidural 
administration of the drug. Epidural fentanyl most probably acts at both 
supraspinal (via systemic delivery) and spinal sites, in addition to drug 
diffusing to spinal receptors from the cerebrospinal fluid. 
NSAIDs: Pain after cesarean delivery may have at least two 
components: postoperative (somatic) pain from the wound itself and 
visceral pain arising from the uterus. Although somatic pain may be 
relieved by opioids, visceral pain may be more difficult to treat. NSAIDs 
are effective for relieving pain related to menstrual cramping and, as a 
result, there has been interest in the use of NSAIDs to treat a component 
of pain after cesarean delivery. Unfortunately, NSAIDs alone are 
insufficient to effectively treat post-cesarean delivery pain. However, 
inclusion of NSAIDs in a multimodal approach to pain relief after 
cesarean delivery has been very successful both in improving the quality 
of analgesia resulting from systemic or neuraxially administered opioids 
and reducing side effects. For instance, use of IM diclofenac 75 mg 
results in a morphine-sparing effect and a decrease in side effects related 
to morphine use. The disadvantages to using NSAIDs relate to the 
potential for gastrointestinal side effects and platelet dysfunction. Also 
COX 2 inhibitors may have a tocolytic action on the uterus and hence 
avoided.  
New Drugs, New Delivery Systems  
Clonidine: Clonidine exerts its antinociceptive effect by 
stimulating the  alpha 2 adrenergic receptor and modulating pain 
pathways in the dorsal horn . It is effective for both somatic and visceral 
pain. The addition of clonidine (up to 100 ug) alone to spinal local 
anesthetic for post-cesarean delivery analgesia has found to cause 
unacceptable degree of hypotension, bradycardia, nausea and vomiting. 
In another study, adding clonidine, 75 or 150 ug, to epidural morphine,  
2 mg, prolonged the duration of analgesia after cesarean delivery from a 
mean +/- sd of 6.27 +/- 1.6 h with morphine alone to 13.25 +/- 3.8 h with 
clonidine 75ug  and 21.55+/- 6.3 h with clonidine  150ug , with the 
combination, without incurring additional side effects(11). A black box 
warning exists prescribing the use of clonidine (or other angiotensin 
converting enzyme inhibitors) during the second and third trimester 
because of the potential for fetal injury and death.  
Dexmedetomidine:  Dexmedetomidine is the other alpha  
2 adrenergic receptor agonist that has recently been approved for iv use. 
Like clonidine, it can cause somnolence, which is undesired in 
postpartum women, but, in general, respiratory variables, such as oxygen 
saturation and respiratory rate, are better maintained with 
dexmedetomidine than with parenterally administered opioids. 
Unfortunately, there is little experience with routine use of the drug in 
postpartum women. At this time, dexmedetomidine is not approved for 
neuraxial use(12) 
Neostigmine: Neuraxial neostigmine produces analgesia by 
inhibiting degradation of acetylcholine in the spinal cord. Results of 
studies using neostigmine for postpartum pain relief have been 
disappointing because of side effects such as nausea, shivering, and 
sedation(13).  
Lipid-Encapsulated Morphine:  Advances in technology have 
allowed for a sustained morphine delivery system to be used with 
epidural analgesia. Depo- Foam™ is a lipid-based vehicle consisting of 
aqueous chambers that encapsulate the active drug, such as morphine 
(DepoDur™), resulting in sustained release and prolonged analgesia 
when the drug is administered epidurally. In one study,  unencapsulated 
morphine was compared with encapsulated morphine at doses of 5, 10, 
and 15 mg administered epidurally at time of cord clamp(14). The 
encapsulated morphine resulted in superior analgesia of longer duration 
than the unencapsulated drug. There are two concerns that maylimit use 
of the drug in obstetrics. First, the Depo- Foam™ vehicle may be lysed in 
the presence of local anesthetic, releasing a relatively large amount of 
morphine in the epidural space and risking  respiratory depression; 
because of this concern, the label for DepoDur ™ is used. 
6. EFFECT OF EPIDURAL & OPIOIDS ON BREAST 
FEEDING 
Barton M et al - Aust Coll Midwives Inc J 1996;9:14 –9   
Postoperative epidural analgesia has been associated with an 
improvement in the mother’s ability to mobilize and interact with her 
newborn infant. 
Hirose et al.(15) randomized 2 groups of 15 patients who underwent 
a cesarean delivery under spinal anaesthesia to receive either 
postoperative epidural analgesia with bupivacaine or IV analgesia. They 
found that mothers receiving epidural bupivacaine for 3 postoperative 
days experienced significantly lower pain scores and had more success 
with breast feeding and greater infant weight gain. In conclusion, it 
appears that early maternal-infant bonding leads to greater success in 
breast feeding as does adequate postoperative pain control. Thus, epidural 
anaesthesia is preferable to general anesthesia, and adequate 
postoperative analgesia is desirable. 
Multiple investgations involving large numbers of patients have 
revealed that Intrathecal and epidural opioids are safe for the mother and 
neonate provided that conventional doses are used.  
Butorphanol is considered effective and safe after cesarean delivery 
with minimal effect on the fetus, and the newborn. Further, the American 
Academy of Pediatrics Committee on Drugs has categorized butorphanol 
as compatible with breast feeding.(16) 
Dose-response study of a combination of 0.25% bupivacaine 
combined with 0,1, 2, or 3 mg of butorphanol was studied in 40 laboring 
parturients. The optimal dose of butorphanol combined with 8.5 to 10 ml 
0.25% bupivacaine was 2 mg. Adverse fetal effects were not observed 
except that of a low amplitude sinusoidal fetal heart rate pattern with 
doses of 3 mg butorphanol. All neonatal observations were normal. It is 
concluded that epidural butorphanol can be a useful and safe adjunct to 
bupivacaine used for epidural analgesia during labor(17) 
Following administration of epidural fentanyl or epidural sufentanil 
to obstetric patients, breast milk conentration of opioid is negligible(18). 
While the elimination half-life of nalbuphine in neonates is 4.1 hr,  
compared to 7-32hrs for pethidine.  Thus, any fetal effects of 
transplacentally/ breast milk transferred opioid will be of shorter duration 
if nalbuphine is used for maternal analgesia, rather than meperidine(19) 
7. VISUAL ANALOGUE SCALE 
A Visual Analogue Scale (VAS) is a measurement instrument that 
tries to measure a characteristic or attitude that is believed to range across 
a continuum of values and cannot easily be directly measured (example - 
the amount of pain that a patient feels ranges across a continuum from 
none to an extreme amount of pain). From the patient's perspective this 
spectrum appears continuous and their pain does not take discrete jumps, 
as a categorization of none, mild, moderate and severe would suggest. It 
was to capture this idea of an underlying continuum that the VAS was 
devised. 
Operationally a VAS is usually a horizontal line, 10cm/100 mm in 
length, anchored by word descriptors at each end. The patient marks on 
the line the point that they feel represents their perception of their current 
state. The VAS score is determined by measuring in centimetres/ 
millimetres from the left hand end of the line to the point that the patient 
marks. 
VAS score has linear scale properties (i.e., the difference in pain 
between each successive increment is equal)(20). Thus, a VAS pain score 
of 6 cm indicates twice as much pain as a VAS score of 3cm, and the 
difference between a VAS score of 3 and 4cm would be of the same 
magnitude as the difference between VAS scores of 7and 8 cm. 
Collins et al(21)  concluded that a VAS score of at least 54mm could 
be equated with a rating of severe pain. The VAS is a unimodal measure 
of pain intensity and cannot adequately represent all aspects of pain 
perception. The extremes of pain—“no pain” and “worst pain ever”—
may not truly represent absolute limits of perception. Despite   these 
limitations, it remains a widely used, validated measure of pain. in 
postoperative patients with acute mild-to-moderate pain, the VAS score is 
a linear scale. Changes in the VAS score represent a relative change in 
the magnitude of pain sensation.  
8. STUDY REVIEWS: 
1. Gambling et al compared postcesarean  outcomes of epidural 
morphine 4 mg plus epidural Butorphanol 3mg versus epidural morphine 
4 mg alone. Patients receiving butorphanol in the study had significantly 
greater analgesia, a significantly lower incidence of treatment for 
pruritus, and significantly greater overall satisfaction compared with 
controls.  
2. Bernard Wiftels et al – In this study saline or 
Butorphanol(BU)  1 or 3 mg was added to epidural morphine 4 mg for 
postcesarean analgesia, there was no difference in analgesic intensity or 
duration; however, parturients who received BU 3 mg had significantly 
less nausea and pruritus than the other two groups(22). No patient 
complained of drowsiness, nor did nursing  personnel observe a greater 
incidence of sedation  among  parturients who had received epidural  
BU (22). These results support the assumption that agonist-antagonist 
opioids are effective in preventing untoward  opioid side effects. 
3. Carl  rosow et al -  Epidural butorphanol has already shown 
some promise in obstetrics. A single dose provides relief of post 
Caesarean pain for six to ten hours without pruritus or excessive sedation. 
4. Quisqueya T. Palacios et al  - Anaesthesia for the Caesarean 
section (T4 sensory level) was produced with lidocaine, two per cent with 
1:200,000 epinephrine, injected through an epidural catheter inserted in 
the L2_3 or L3-4 interspace.. The test medications were morphine, 5 mg, 
and butorphanol 1, 2, or 4 mg. The time to onset of epidural analgesia 
following butorphanol was more rapid than following morphine. 14, 22 
and 17 per cent of patients treated with butorphanol 1,2 or 4 mg 
respectively, had not requested supplemental medication at eight hours, 
65 per cent of the morphine patients had not been remedicated at eight 
hours. Pruritus occurred in only 1.4 per cent of the Butorphanol patients 
compared with 43 per cent of the morphine patients(23). 
5. Szabova A et al- postoperative epidural butorphanol / 
bupivacaine with the gold-standard epidural analgesic infusion fentanyl / 
bupivacaine in children. Epidural butorphanol provided similar analgesia 
to epidural fentanyl after urological procedures in children, but 
butorphanol caused less pruritus than fentanyl.  Epidural analgesia with 
butorphanol/bupivacaine is effective in children undergoing urological 
procedures. When compared with epidural fentanyl, epidural butorphanol 
causes significantly less itching. 
6. J S Naulty et al  (Anaesthesiology v81, sep 1994) Epidural 
Butorphanol after delivery of baby 1mg, 2mg, 4mg, results showed 
increasing duration of analgesia as dose increases, but no statistical 
significance. No case reported pruritus. 80% of cases reported 
somnolence. 
7. Baxter AD et al - Can J Anaesth 1991;38:175-82. 
Nalbuphine (NB)  is a mixed agonist-antagonist opioids with only modest 
analgesic properties after epidural administration.  After cesarean 
delivery with epidural lidocaine, epidural NB in doses of 10,20, and 30 
mg promoted satisfactory analgesia, but with a duration of only 1-3 h(24) 
8. Weksler and Ovadia et al administered 0.15 mg/kg  
nalbuphine epidurally to 30 patients following upper abdominal surgery, 
which produced a mean duration of analgesia of 6.5 hr.(25) following 
upper abdominal surgery, which produced a mean duration of analgesia 
of 6.5 hr. Somnolcence was the only bothersome side-effect, occurring in 
55% of the patients; however, no patient developed respiratory depression 
as measured by sequential arterial PaCO2 measurements for 24 hr. 
9. McMorland  et al reported only fair and inconsistent 
analgesia following epidural Nalbuphine (dose range 5-20 mg) after 
Caesarean delivery in 40 patients. Side-effects were minimal and the 
respiratory response to a CO2 challenge at three and six hours after 
epidural opioid was unaffected. 
10. Thoracic epidural nalbuphine (0.075-0.3 mg.kg -I) has been 
found by Baxter et al. to be an ineffective analgesic for post-thoracotomy 
patients. These authors found no evidence of a dose-response effect in the 
nalbuphine dose-range studied. Moreover, the pharmacokinetic profile of 
epidural nalbuphine was similar to that seen with iv injection(26). 
11. Culebras X et al   -   2000-09, Anesth Analg., 91(3):601-5. 
Intrathecal nalbuphine, at three different doses, and intrathecal morphine 
for postoperative pain relief after cesarean deliveries. Ninety healthy 
patients at full term who were scheduled for elective cesarean delivery 
with spinal anaesthesia were enrolled in the study. They received 10 mg 
of hyperbaric bupivacaine 0.5% with either morphine 0.2 mg (Group 1), 
nalbuphine 0.2 mg (Group 2), nalbuphine 0. 8 mg (Group 3), or 
nalbuphine 1.6 mg (Group 4).  Postoperative analgesia lasted 
significantly longer in the morphine group, compared with the nalbuphine 
groups (P: < 0.0001).  In the nalbuphine groups, postoperative analgesia 
lasted longest with the 0.8-mg dose. The additional increase to 1.6 mg did 
not increase efficacy. The incidence of pruritus was significantly higher 
in Group 1 (11 of 22), compared with Group 2 (0 of 22, P: < 0.0002), 
Group 3 (0 of 23, P: < 0.0001), and Group 4 (3 of 20, P: < 0.02). 
Postoperative nausea and vomiting were more frequent in Group 1 (5 of 
22), compared with Group 2 (0 of 22, P: < 0.05), Group 3 (0 of 23, P: < 
0.05), and Group 4 (3 of 23, not significant). There was no maternal or 
newborn respiratory depression. Neonatal conditions (Apgar scores and 
umbilical vein and artery blood gas values) were similar for all groups. 
This study suggests that intrathecal nalbuphine 0.8 mg provides good 
intraoperative and early postoperative analgesia without side effects. 
However, only morphine provides long-lasting analgesia but with 
unwanted side effects. 
12. Camann WR et al - 1991-09, Can J Anaesth., 38(6):728-32. 
Epidural Anaesthesia with local anaesthetics – Lignocaine & 
Chlorprocaine was carried out, and postoperatively the effect of 
Nalbuphine in doses of 10mg, 20mg & 30mg were studied. The results of 
this study suggests that epidural nalbuphine (20 or 30 mg) provides only 
two to four hours of effective analgesia following Caesarean delivery, 
and then only in the presence of some degree of residual lidocaine 
anaesthesia. When 2-CP was used as the primary local anaesthetic agent, 
postoperative epidural nalbuphine (regardless of dose) failed to provide 
any analgesic effects in the absence of residual local anaesthetic block (27). 
13. Orawan Pongraweewan et al (J Med Assoc Thai 2009; 92 
(6): 782-6) purpose of the study was to test the clinical efficacy of 
epidural nalbuphine 5 mg and 10 mg for prevention of morphine-induced 
pruritus. Epidural Nalbuphine 10 mg reduced the incidence of pruritus for 
6 h was the conclusion. 
14. Wittles et al found that epidural nalbuphine 10 mg reduced 
the incidence of pruritus from 48% to 20% for 6 h(28) 
15. Hunt et al.  conducted a randomized study that demonstrated 
a dose-dependent increase in postcesarean delivery analgesia up to a 
fentanyl dose of 6.25 ug, beyond which there was no added advantage. 
Furthermore, mean duration of effective analgesia was only 200 min. 
  
 AIM OF THE STUDY 
 
 Comparison and study of post cesarean analgesia and side effect 
profile of epidural 0.125% bupivacaine-fentanyl v/s 0.125% bupivacaine-
nalbuphine v/s 0.125% bupivacaine – butorphanol.  
METHODOLOGY 
After getting Ethical committee approval, 80 parturients belonging 
to ASA physical status I & II undergoing Elective LSCS were enrolled.  
INCLUSION CRITERIA 
 ASA Class I & II  
 Elective cesarean section  
EXCLUSION CRITERIA 
 ASA Class III & IV (Severe PIH, Stenotic Valvular Heart disease) 
Emergency Surgery (Includes Fetal distress, threatened rupture,       
hemodynamic compromise). 
 Not willing for Epidural 
 Psychiatric patients 
 Bleeding diathesis 
 H/o. hypersensitivity to Opioid /LA  
In the preanaesthetic visit, all the patients were made familiar with 
the study plan. Respiratory rate, Non invasive blood pressure, peripheral 
arterial saturation and heart rate were monitored throughout the 
perioperative period. Patients were monitored with pulse oximetry, NIBP 
& ECG. Respiratory rate also was recorded. 
Intravenous Hydration with 12-15ml/kg of fluid prior to surgery. 
Epidural Catheter is placed in L2-L3 or L3-L4 interspace. Approximately 
4cm of catheter was kept inside the space. A test dose of 2ml of 0.5% 
Bupivacaine was given via catheter before it is fixed. After confirming 
the epidural placement of the catheter, incremental doses of 0.5% 
Bupivacaine(5cc) was given until a bilateral T6 sensoroy level 
(determined by pin prick) was attained. Till the incision time parturient 
was placed in operating table in a left lateral tilt.  Oxygen at 4L/min via 
venturi mask was provided. If there was any hypotension (MAP <  
60 mm Hg) Inj. Ephedrine 6mg iv was given along with intravenous 
fluid. If the Heart rate fell below 50/mt, Inj Atropine 0.6mg iv was given. 
Epidural route was used for surgery & postoperative analgesia. If 
the epidural block failed, regional anaesthesia was converted to General 
Anaesthesia and the parturient was excluded from the study.  Opioid was 
not administered during the intraoperative period. After the surgery was 
over parturients were shifted to labour ward postoperative recovery room.  
The parturients were observed for pain on a 10cm VAS. When the 
epidural effect of local anaesthetic given in the intraoperative period was 
wearing off & when they complained of  pain (VAS of 5cm), they were 
classed into four groups randomly as follows & study drugs were given 
epidurally for the respective groups. 
Group 1 (NS): 20 parturients receiving 10ml of 0.125% 
Bupivacaine + 1ml of Normal Saline (Total = 11ml) 
Group 2 (FENT): 20 parturients receiving 10ml of 0.125% 
Bupivacaine +  50ug of Fentanyl (1ml) (Total = 11ml) 
Group 3 (NALB): 20 parturients receiving 10ml of 0.125% 
Bupivacaine + 5mg of Nalbuphine(0.5ml) +0.5ml of Normal saline to 
make it into 1ml (Total = 11ml) 
Group 4 (BUTOR): 20 parturients receiving 10ml of 0.125% 
Bupivacaine + 1mg of Butorphanol (1ml) (Total = 11ml) 
Pain score was observed at 2min, 4min, 6min, 8min, 10 min, 15 
min, 20 min, 25 min, 30min & then every ½ hourly intervals upto 10hrs  
on a 10cm VAS (‘no pain’ at 0 cm end and ‘worst pain ever’ at 10cm  
end). The observer assessing pain was kept blinded for the epidural 
medication. Thereafter, continuous measurement of pain by VAS was 
made at intervals till the patient was completely free of pain (VAS 0). If 
the VAS score failed to decline atleast by 1cm even after 30 min of 
epidural injection, the patient was given intramuscular diclofenac sodium 
75 mg and was excluded from the study.  
The onset of analgesia was defined as the time from injection of the 
study medication to first reduction in pain intensity by at least 1cm in 
VAS; the onset of peak analgesia was defined as the time to achieve the 
lowest VAS score; and the duration of analgesia was defined as the time 
between the onset of analgesia and either a  return to baseline VAS of 
5cm (after which patients were given i.m diclofenac & study concluded). 
If any patient demanded pain relief before the study could be completed 
they were also given i.m diclofenac & were excluded from the study.  
The quality of analgesia was assessed based on the overall satisfaction of 
the patient and the time of the first changing of positions side to side 
independently in the bed. The overall satisfaction of the patient was 
assessed with a 10 cm scale of VAS Satisfaction (‘no satisfaction’ at 0 cm 
end and ‘the best satisfaction’ at 10 cm end). Motor block if any was 
assessed using the Bromage Score.  
Sedation was assessed when the VAS score reached the minimum 
(using Modified Ramsay sedation score). The occurrence of nausea and 
vomiting, pruritus  and respiratory depression (respiratory rate <10/min) 
was noted up to 24 hours following administration of the study 
medication.  
The collected data was analyzed statistically: Analysis of variances 
(ANOVA) was used for comparison of mean values between more than 
two groups; Posthoc test was used to find any significance between the 
individual groups, Chi square test was used to compare the discrete 
variables between groups. A p value of <0.05 was considered significant.  
SCALES & SCORES USED 
VISUAL ANALOGUE SCALE 
“Please make a mark on this line that describes how much pain you 
are having” 
No          0___1___2___3___4___5___6___7___8___9___10 Worst    
pain                imaginable  pain 
PATIENT SATISFACTION SCALE: 
 
Completely 
Dissatisfied                
Completely 
Satisfied 
 0  1  2  3  4  5  6  7  8  9  10  
                       
            
                       
 
 
BROMAGE SCALE: 
Grade Criteria Degree of block 
I Free movement of legs and feet Nil (0%) 
II Just able to flex knees with free movement 
of feet 
Partial (33%) 
III Unable to flex knees, but with free 
movement of feet 
Almost complete 
(66%) 
IV Unable to move legs or feet Complete (100%) 
 
Modified Ramsey Sedation Scale 
1. anxious and agitated or restless, or both 
2. co-operative, oriented, and calm 
3. responsive to commands only 
4. exhibiting brisk response to light glabellar tap or loud auditory 
stimulus 
5. exhibiting a sluggish response to light glabellar tap or loud 
auditory stimulus 
6. unresponsive 
Nausea / vomiting  
0- No nausea/vomiting 
1- Nausea 
2- Vomiting 
0 - No pruritus 
1- Pruritus  
Independent change of  position   
 
Patient able to change position side to side freely - 1 
Not able to change position because of pain/discomfort – 0 
 
Bradycardia HR < 50/min  
0 - No Bradycardia 
1- Presence of Bradycardia 
 
Respiratory depression 
RR < 10/mt  
0 - No Respiratory depression 
1 - Presence of Respiratory depression 
 
Desaturation: SPO2 < 95% 
0 - No desaturation 
1 - Presence of desaturation 
 
Hypotension 
Systolic BP < 80 mm Hg 
MAP < 60 mm Hg 
 RESULTS 
The data of only 77 patients were included for calculation because 
three patients were dropped from the study as they had patchy sensory 
blockade to an extent of converting to GA.There was no statistically 
significant difference in demographic parameters (age, height, weight); 
Indication for epidural; Epidural insertion space, volume of local 
anaesthetic given(0.5% Bupivacaine) (p value- 0.578) & duration of 
surgery (p value – 0.654) in the four groups.  
Serial 
No. Parameter 
Group 
NS 
(n=18) 
Group  
FENT 
(n=20) 
Group 
NALB 
(n=19) 
Group 
BUTOR 
(n=19) 
P value 
1 Age (yrs) 26.22 26.20 25.42 25.63 0.766 
2 Weight(kg) 61.33 60.05 62.74 62.16 0.707 
3 Height(cm) 159.28 159.50 159.42 158.84 0.985 
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NS FENT NALB BUTOR
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158.5
158.6
158.7
158.8
158.9
159
159.1
159.2
159.3
159.4
159.5
NS FENT NALB BUTOR
159.28
159.5
159.42
158.84
HT IN CMS
HT
  
 
 
 
 
 
 
 
 
 Mean onsets of analgesia and times to reach peak analgesia were 
significantly shorter while the mean durations of analgesia were 
significantly longer in the groups receiving fentanyl, nalbuphine & 
butorphanol than in the group receiving bupivacaine alone. Also there is a 
statistical significance between individual groups. The onset of analgesia 
was earliest with Butorphanol group followed by fentanyl group,  
Nalbuphine group & finally by control group. The onset  of peak 
analgesia occurred first in the Butorphanol group followed by fentanyl 
group,  Nalbuphine group & finally by control group. The  duration of 
analgesia was maximum with Butorphanol group (mean of 360 min 
approx), followed by Fentanyl group (mean of 279 min approx), 
Nalbuphine group (mean of 246 min approx) & control group (mean of 
212min approx).  
Sl. 
No. 
Parameter      
(min) 
Group 
NS 
(n=18) 
Group  
FENT 
(n=20) 
Group 
NALB 
(n=19) 
Group 
BUTOR 
(n=19) 
P value 
1 Onset of analgesia 8.22 4.20 5.42 
3.42 0.000 
2 Peak onset of analgesia 21.39 8.65 10.16 
 
8.42 
 
0.000 
3 Duration of analgesia 211.94 279.20 245.53 
 
360.11 
 
0.000 
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VAS PROGRESSION IN THE GROUPS
CONTROL
FENTANYL
NALBUPHINE
BUTORPHANOL
0
50
100
150
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300
350
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NS FENT NALB BUTOR
211.94
279.2
245.53
360.1
DURATION OF ANALGESIA 
DURATION OF ANALGESIA IN 
MIN
Satisfaction with the pain relief given was assessed by  
  1. Ability for independent side to side movement   
2. VAS for satisfaction.  
It was observed that, mothers of Butorphanol group was able to 
turn side to side for feeding their babies, instead of the surgical trauma, 
better than nalbuphine group, fentanyl group & control group in the 
descending order. It was also observed that satisfaction was more with 
Butorphanol group followed by Nalbuphine group, Fentanyl group & by 
control group in the descending order. 
Sl. 
No. 
Parameter      
(min) 
Group 
NS 
(n=18) 
Group  
FENT 
(n=20) 
Group 
NALB 
(n=19) 
Group 
BUTOR 
(n=19) 
P value 
1 
Independent 
Change of 
position 
22% 30% 42% 
84% 0.001 
2 VAS for Satisfaction 4.33 5.45 6.42 
 
7.11 
 
 
0.000 
 
  
  
 
There were no motor blockade observed in any of the study groups 
(Bromage score was Grade I). 
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INDEPENDENT CHANGE OF 
POSITION
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PATIENT SATISFACTION VAS
PATIENT SATISFACTION 
VAS
 Nausea & Vomiting was observed in both control group (incidence 
of 6%)  & fentanyl group (incidence of 20%) 
Sl 
No. 
Parameter – 
Incidence 
Group NS 
(n=18) 
Group  
FENT 
(n=20) 
Group 
NALB 
(n=19) 
Group    
BUTOR 
(n=19) 
P 
value 
1 
Nausea-
vomiting 
5.55 % 20 % - - 
0.000 
2 Pruritus - 15 % - - 0.033 
3 Sedation 16.66 % 25 % 57.89 % 63.16% 0.000 
No patient in any of the group had Respiratory depression, Bradycardia, 
Hypotension, Desaturation 
 
Pruritus was observed only in the fentanyl group with a incidence 
of 15% . 
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 Sedation was observed in all the groups (Control – 17%, Fentanyl 
– 25%, Nalbuphine – 58%, Butorphanol – 63%. Butorphanol & 
Nalbuphine groups had more incidence of sedation & higher grades of 
sedation (Grade 4). 
 
 
 
 
 
 
None of the patients developed hypotension, Bradycardia, 
respiratory depression. 
DISCUSSION 
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PRURITUS
The analgesic efficacy & side effects of Epidural 0.125% 
Bupivacaine + Normal saline; 0.125% Bupivacaine + fentanyl  50ug; 
0.125% Bupivacaine + Nalbuphine 5mg & 0.125% Bupivacaine + 
Butorphanol 1mg were studied.  
1. The onset of analgesia was earlier & the duration of 
analgesia was prolonged in all the opioid groups when compared to the 
control group. The study has once again confirmed that combination of an 
opioid and a local anesthetic enhances the onset and prolongs the duration 
of analgesia more than the local anesthetic alone. 
Results of our study correlate with study done by Abboud and 
coworkers who found significantly better quality of analgesia in 
parturients receiving epidural bupivacaine with butorphanol than with 
bupivacaine alone(29), (epidural LA with opioid better than LA alone) 
Shrestha et al, in his study has shown that 2 mg of epidural 
butorphanol added to a lower concentration of bupivacaine (0.1%) 
provided a better quality of labor analgesia than 0.25% bupivacaine 
alone.(30) (epidural LA with opioid better than LA alone) which again 
correlate with our study. 
2. Butorphanol in addition to bupivacaine produce earlier onset 
and longer duration of analgesia than Nalbuphine & Fentanyl in epidural 
analgesia. Epidural Butorphanol with bupivacaine also had better patient 
satisfaction in terms of VAS for Satisfaction and ability for independent 
movement (position change).  
Pokharel K et al in his study, Low dose (0.5 mg) of epidural 
butorphanol with bupivacaine 0.125% was studied in parturients 
following cesarean delivery. Parturients were allocated into two groups: 
group 1 received epidural 0.125% bupivacaine while group 2 received an 
additional of  0.5 mg butorphanol(31). The epidural route was used for 
postoperative analgesia with the study drug. The onset and duration of 
analgesia in group 2 (4.1+/-2.6 min and 202.4+/-62.8 min) were 
significantly different (P<0.01) from group 1 (6.6+/-2.7 min and 145.7+/-
89.6 min). Results we obtained were (Butorphanol group - onset of 
analgesia was  3.42 min, duration of analgesia was 360 min  & NS group 
- onset of analgesia was  8.22 min, duration of analgesia was 211 min). 
Both the results are comparable, except for an early onset of analgesia & 
prolonged duration of analgesia we obtained in our study, which could 
probably attributed to a little higher dose (1mg of butorphanol) used in 
our study. 
Gupta R et al in his study on Post operative analgesia in patients 
undergoing lower limb surgery with 2 mg butorphanol as bolus epidurally 
diluted in 10 ml normal saline, found the duration of analgesia to be 
5.35±0.29 hrs. The duration of analgesia in this study was comparable to 
our study (duration = 360min).(32) 
3. Nalbuphine in combination with bupivacaine produced delay 
onset & shorter duration of analgesia when compared to Fentanyl & 
Butorphanol groups, but definitely earlier onset and longer duration of 
analgesia than bupivacaine alone. 
Though the onset of analgesia was delayed and duration of 
analgesia was short in the Nalbuphine group when compared to the 
fentanyl group, patient satisfaction was better in the Nalbuphine group, 
probably  because the side effects like nausea/vomiting; pruritus are less 
with Nalbuphine compared to Fentanyl. 
Baxter AD et al in his study, demonstrated that after cesarean 
delivery with epidural lidocaine, epidural Nalbuphine in doses of 10,20, 
and 30 mg promoted satisfactory analgesia, but with a duration of only  
1-3 h(33) 
Pugh GC  et al(34), in his study mentioned nalbuphine as an 
analgesic agent provides a number of advantages. Used as the sole opioid 
analgesic, it can satisfactorily cover mild to moderate pain with a low 
incidence of side effects. The ceiling effect of nalbuphine, which prevents 
it from supplying sufficient analgesia to cover the most severe 
discomfort, also prevents increasing sedation and respiratory depression 
as the dose is increased, potentially providing an increased safety margin 
in comparison to mu-agonists. When nalbuphine is used concurrently 
with mu-agonists (e.g. morphine, fentanyl) the benefits of both mu- and 
kappa-analgesia can be obtained, with simultaneously decreased 
incidence and severity of the common mu-agonist side effects (pruritis, 
nausea/emesis, constipation, urinary retention, respiratory depression and 
undesirable sedation). 
4. Though the incidence of sedation is more in Butorphanol & 
Nalbuphine groups, all the patients were easily arousable. butorphanol is 
associated with profound dose-dependent sedation with reported 
somnolence in more than 50% of patients at doses 2 mg or more.(35) 
In our study we have used only 1mg epidurally, hence the sedation 
cannot be fully attributed to the drug. The contribution of factors such as 
sleep deprivation, exhaustion and anxiety during surgery renders the 
patients drowsy or sleepy cannot be denied 
5. In the study, we did not observe nausea and vomiting  in 
Butorphanol & Nalbuphine groups. Fentanyl group had nausea & 
vomiting upto 20% more than control group(5.55%) 
Cohen et al in his study for postcesarean analgesia, found epidural 
bupivacaine when combined fentanyl had more more nausea and 
vomiting than bupivacaine alone(36) which correlates with our study.  
6. In the study, we did not observe pruritus in Butorphanol & 
Nalbuphine groups  which could be compared with the following studies; 
J S Naulty et al in his study on epidural Butorphanol after delivery 
of baby 1mg, 2mg, 4mg in 40 parturients, results showed increasing 
duration of analgesia as dose increases, but no statistical significance. No 
case reported pruritus. somnolence. 
Prophylactic administration of butorphanol has been recommended 
for prevention of such side effects produced by pure agonist opioids like 
morphine and it has also been effectively used for the treatment of 
intractable pruritis associated with dermatological conditions(37) 
Wittles et al found that epidural nalbuphine 10 mg reduced the 
incidence of pruritus from 48% to 20% for 6 h(38)  
  
 CONCLUSION 
Epidural 0.125% Bupivacaine combined with Butorphanol  
produces significantly earlier onset, longer duration and better quality of 
analgesia than 0.125% Bupivacaine - Nalbuphine  combination /  0.125% 
Bupivacaine -Fentanyl combination / 0.125% Bupivacaine alone and is 
safe in parturients. 
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PROFORMA 
 
NAME:                    AGE:   GRAVIDA: 
OCCUPATION:    ADDRESS:  WEIGHT: 
ANAESTHETIST: 
PREOPERATIVE  CLINICAL ASSESMENT:   
H/O  MEDICAL / SURGICAL ILLNESS: 
PALLOR/CLUBBING/PEDAL EDEMA/CYANOSIS: 
 CVS:      VITALS:   PR- 
 RS:          BP- 
OTHER  SYSTEMS: 
INVESTIGATIONS: 
BLOOD  HB%:  RFT:    BLOOD SUGAR:     
  
 
ECG: 
AIRWAY: 
ASA PHYSICAL STATUS: 
 PREOPERATIVE CLINICAL ASSESMENT ON THE DAY OF SURGERY: 
 
 
 
 
 
 
 
PROFORMA FOR STUDY GROUP     __________________ 
S.
N
O
 Variable Data  VAS  
 Anaesthetist  2 min  
1. Name  4 min  
2. Age  6min  
3. IP No.  8 min  
4. Gravida  10 min  
5. Indication  15 min  
7. Comorbid Illness   20 min  
8. Height  25 min  
9.  Weight  30 min  
10. ASA  1 hr  
11 Epidural space  1 ½ hr  
12 Catheter length inside space  2 hr  
13. Vol. of 0.5% sensorcaine  2 ½ hr  
14. Highest level achieved  3 hr  
15.  Incision Time  3 ½ hr  
16. Time of baby delivery  4 hr  
17. Time at which surgery was finished  4 ½ hr  
18. Duration of Surgery  5 hr  
19. Time at which pain (VAS = 5) in 
postoperative  period 
 5 ½ hr  
20. Duration of motor block  6 hr   
21. Motor blockade grade  6 ½ hr  
22. Duration of Analgesia  7 hr   
23. Nausea/Vomiting  8 hr  
24. Pruritus  9 hr  
25. Sedation grade  10 hr  
26. Respiratory depression  Onset of 
analgesia 
duration 
 
27. Hypotension  Peak onset of 
analgesia 
 
28. Bradycardia  Duration of 
analgesia 
 
29. Desaturation  Independent 
change of 
position 
 
   VAS for 
satisfaction 
 
 
 
 
MASTER CHART: FOUR GROUPS 
 

 
